IP Library › Granted Patent US 12,533,374
Granted Patent B2
US 12,533,374 · App. 17/922,229 · Granted Jan 27, 2026

Compositions and methods of use thereof

Inventors: Shenda M. Baker (Upland, CA); William P. Wiesmann (Chevy Chase, MD)
Assignee: SYNEDGEN, INC.
A61K31/726A61P31/04A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,374
App. No.
17/922,229
Granted
Jan 27, 2026
Kind
B2
Abstract

Described herein are methods of treating a Nontuberculosis Mycobacteria (NTM) infection in a subject in need thereof, the methods comprising administering an effective amount of a polyglucosamine derivative or a composition comprising a polyglucosamine derivative.

Claims (33)

1 . A method of treating an acute or chronic nontuberculosis mycobacteria (NTM) infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a poly(acetyl, arginyl) glucosamine (PAAG) comprising the following Formula (I):

wherein:

n is an integer between 20 and 6000; and each R 1 is independently selected for each occurrence from hydrogen, acetyl,

wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and at least 2% of R 1 substituents are

wherein the subject is unresponsive to a previously administered NTM therapy; and

wherein the treatment comprises achieving a negative NTM cell sputum culture of the subject.

2 . The method of claim 1 , wherein the NTM cells are NTM persister cells, NTM cells in stationary growth phase, slow growing NTM cells, or rapidly growing NTM cells, or a combination thereof.

3 . The method of claim 1 , wherein the NTM cells are NTM persister cells.

4 . The method of claim 1 , wherein the NTM infection is caused by bacteria selected from the group consisting of Mycobacterium avium complex (MAC), Mycobacterium abscessus complex (MABSC), Mycobacterium gordonae , and Mycobacterium intracellular , or a combination thereof.

5 . The method of claim 1 , wherein the method comprises disrupting a biofilm caused by the NTM infection.

6 . The method of claim 1 , wherein the method comprises disrupting mucus comprising a biofilm caused by the NTM infection.

7 . The method of claim 6 , wherein the disrupting reduces adhesion of the mucus to pulmonary epithelia.

8 . The method of claim 1 , wherein the method comprises inhibiting regrowth of a biofilm comprising NTM.

9 . The method of claim 1 , wherein the subject has a lung disease, cystic fibrosis (CF), chronic pulmonary disorder, primary ciliary dyskinesia, or non-CF bronchiectasis.

10 . The method of claim 1 , wherein the subject has been previously administered an NTM therapy.

11 . The method of claim 10 , wherein the NTM therapy is an antibiotic.

12 . The method of claim 11 , wherein the antibiotic is rifampicin, aztreonam, ethambutol, amikacin, azithromycin, or clarithromycin, or a combination thereof.

13 . The method of claim 1 , wherein the subject is concurrently administered a second NTM therapy.

14 . The method of claim 1 , further comprising administering to the subject an additional therapeutic agent.

15 . The method of claim 14 , wherein the additional therapeutic agent is selected from the group consisting of an antibiotic agent, an anti-inflammatory agent, and a vasodilator, or a combination thereof.

16 . The method of claim 14 , wherein the PAAG is administered to the subject prior to administration of the additional therapeutic agent.

17 . The method of claim 14 , wherein the PAAG is administered to the subject concurrently with administration of the additional therapeutic agent.

18 . The method of claim 14 , wherein the PAAG is administered to the subject subsequent to administration of the additional therapeutic agent.

19 . A method of treating an acute or chronic nontuberculosis mycobacteria (NTM) infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a poly (acetyl, arginyl) glucosamine (PAAG) comprising the following Formula (I):

wherein:

n is an integer between 20 and 6000; and each R 1 is independently selected for each occurrence from hydrogen, acetyl,

wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and at least 2% of R 1 substituents are

wherein the subject is unresponsive to a previously administered NTM therapy; and

wherein the treatment results in an undetectable amount of NTM cells in the subject.

20 . A method of eradicating an entire population of nontuberculosis mycobacteria (NTM) cells in an environment selected from the group consisting of a subject, a sample, a biofilm, a surface, and a medical device, the method comprising administering to the environment an effective amount of a poly (acetyl, arginyl) glucosamine (PAAG) comprising the following formula comprising the following Formula (I):

wherein:

n is an integer between 20 and 6000; and each R 1 is independently selected for each occurrence from hydrogen, acetyl,

wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and at least 2% of R 1 substituents are

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2023
From: BAKER, SHENDA M.; WIESMANN, WILLIAM P.
To: SYNEDGEN, INC.
Reel/Frame 062480/0503 →
Continuity (1)
Related Publication 20230201248A1 · Jun 29, 2023
References Cited (88)
US 8119780B2 · Baker et al. · 2012 [cited by applicant]
US 8399635B2 · Baker et al. · 2013 [cited by applicant]
US 8658775B2 · Baker et al. · 2014 [cited by applicant]
US 8916542B2 · Baker et al. · 2014 [cited by applicant]
US 9012429B2 · Baker et al. · 2015 [cited by applicant]
US 9029351B2 · Baker et al. · 2015 [cited by applicant]
US 9234050B2 · Baker et al. · 2016 [cited by applicant]
US 9439925B2 · Baker et al. · 2016 [cited by applicant]
US 9732164B2 · Baker et al. · 2017 [cited by applicant]
US 20030087414A1 · Aerts et al. · 2003 [cited by applicant]
US 20030181416A1 · Comper · 2003 [cited by applicant]
US 20040242626A1 · Achari et al. · 2004 [cited by applicant]
US 20060140911A1 · Sharp et al. · 2006 [cited by applicant]
US 20070117783A1 · Brueck-Scheffler · 2007 [cited by applicant]
US 20070281904A1 · Baker et al. · 2007 [cited by applicant]
US 20090304664A1 · Lindquist et al. · 2009 [cited by applicant]
US 20100056474A1 · Baker et al. · 2010 [cited by applicant]
US 20120295355A1 · Baker et al. · 2012 [cited by applicant]
US 20120301408A1 · Baker et al. · 2012 [cited by applicant]
US 20120329751A1 · Baker · 2012 [cited by examiner]
US 20130019860A1 · Depla et al. · 2013 [cited by applicant]
US 20130210761A1 · Baker et al. · 2013 [cited by applicant]
US 20140080785A1 · Baker et al. · 2014 [cited by applicant]
US 20140221308A1 · Baker et al. · 2014 [cited by applicant]
US 20140234310A1 · Shapiro · 2014 [cited by applicant]
US 20150031610A1 · Baker et al. · 2015 [cited by applicant]
US 20150224044A1 · Baker et al. · 2015 [cited by applicant]
US 20160022564A1 · Townsend et al. · 2016 [cited by applicant]
US 20160022730A1 · Baker et al. · 2016 [cited by applicant]
US 20160060362A1 · Baker et al. · 2016 [cited by applicant]
US 20170119810A1 · Baker et al. · 2017 [cited by applicant]
US 20170136056A1 · Baker et al. · 2017 [cited by applicant]
US 20170304355A1 · Baker et al. · 2017 [cited by applicant]
US 20200009182A1 · Baker et al. · 2020 [cited by applicant]
US 20200009183A1 · Baker · 2020 [cited by examiner]
JP 2009522328A · 2009 [cited by applicant]
JP 2010507617A · 2015 [cited by applicant]
WO WO0036915A1 · 2000 [cited by applicant]
WO WO07077164A1 · 2007 [cited by applicant]
WO WO2007142704A3 · 2008 [cited by applicant]
WO WO2008072230A1 · 2008 [cited by applicant]
WO WO08049842A3 · 2008 [cited by applicant]
WO WO2010056927A1 · 2010 [cited by applicant]
WO WO2011028967A1 · 2011 [cited by applicant]
WO WO2011028968A1 · 2011 [cited by applicant]
WO WO2011028968A8 · 2011 [cited by applicant]
WO WO2013134129A3 · 2015 [cited by applicant]
WO WO2016040899A1 · 2016 [cited by examiner]
WO WO2016172595A1 · 2016 [cited by applicant]
WO WO2021221656A1 · 2021 [cited by applicant]
WO WO2021222727A1 · 2021 [cited by applicant]
Tre-Hardy, et al., “In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures”, International Journal of Antimicrobial Agents, Elsevier Science, Amsterdam, NL., vol. 31,… [cited by applicant]
Tin San, et al., “Activity of Chitosans in combination with antibiotics in Pseudomonas aeruginosa” International Journal of Biological Sciences, vol. 5., No. 2, Mar. 1, 2009. [cited by applicant]
Supplementary European Search Report dated Apr. 10, 2013 for EP 10 81 4536. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2010/047758, dated Nov. 1, 2010. [cited by applicant]
Singh, P. K. et al., Nature, “Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms”, Oct. 2000, vol. 407, pp. 762-764. [cited by applicant]
Extended European Search Report for EP application No. 17182792.6, dated Mar. 2, 2018. [cited by applicant]
Full Examination Report for Australian Patent Application No. 2015314755, dated Jan. 29, 2019. [cited by applicant]
International Search Report and Written Opinion for PCT/US2015/049835, dated Dec. 31, 2015. [cited by applicant]
Supplementary European Search Report mailed on Mar. 22, 2018 for EP 15840207. [cited by applicant]
European Search Opinion mailed on Mar. 22, 2018 for EP15840207. [cited by applicant]
Deneuville et al. “Revisited Physicochemical and Transport Properties of Respiratory Mucus in Genotyped Cystic Fibrosis Patients” American Journal of Respiratory Critical Care Medicine. 1997, vol. 156 pp. 166-172. [cited by applicant]
Actor et al. “Lactoferrin as a Natural Immune Modulator” Curr Pharm Des. 2009, vol. 15, pp. 1956-1973. [cited by applicant]
Sharma et al. “Antibiotics versus biofilm: an emerging battleground in microbial communities”, Antimicrobial Resistance and Infection Control (2019) 8:76. [cited by applicant]
Flemming, et al. “The EPS Matrix: The House of Biofilm Cells”, Journal of Bacteriology, Nov. 2007, p. 7945-7947. [cited by applicant]
Herrero R, et. al. “New insights into the mechanisms of pulmonary edema in acute lung injury.” Ann Transl Med 2018;6(2):32. doi: 10.21037/atm.2017.12.18. [cited by applicant]
Jiang et al. “Regulation of lung injury and repair by Toll-like receptors and hyaluronan” Nature, (2005) pp. 1173-1179. [cited by applicant]
Pechos RD “With Friends Like These: The Complex Role of Neutrophils in the Progression of Severe Pneumonia”, Front. Cell. Infect. Microbiol. 7:160. [cited by applicant]
Yang S-C et al., “Understanding the role of neutrophils in acute respiratory distress syndrome.” Biomedical Journal, http://doi.org/10/1016/j.bj.2020.09.001. [cited by applicant]
Maria Cristina Bonferoni et.al. (2009) Chitosan and its salts for mucosal and transmucosal delivery, Expert Opinion on Drug Delivery, 6:9, 923-939, DOI: 10.1517/17425240903114142. [cited by applicant]
Khalil, H. et al., Antimicrobial Agents and Chemotherapy, “Synergy between Polyethylenimine and Different Families of Antibiotics against a Resistant Clinical Isolate of Pseudomonas aeruginosa”, 2008, vol. 52, No. 5, pp… [cited by applicant]
Narayanaswamy et al, (2018) “Novel Glycopolymer Eradicates Antibiotic- and CCCP-Induced Persister Cells in Pseudomonas aeruginosa,” Front. Micbrobiol, 9:1724. [cited by applicant]
Robert C. Read et al. “Effective nasal influenza vaccine delivery using chitosan”. Vaccine 23 (2005) 4367-4374. [cited by applicant]
International Search Report and Written Opinion issued for PCT/US20/30702, mailed on Jul. 27, 2020 (8 pages). [cited by applicant]
International Search Report and Written Opinion issued for PCT/US21/30132, mailed on Sep. 9, 2021. [cited by applicant]
Johnson et al., “Nontuberculous mycobacterial pulmonary infections” [cited by applicant]
Henkle et al., “Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts” [cited by applicant]
Johnson et al., “Nontuberculous mycobacterial pulmonary infections” [cited by applicant]
Narayanaswamy et al., “In Vitro Activity of a Novel Glycopolymer against Biofilms of [cited by applicant]
Fang et al., “Characterization of [cited by applicant]
Garcia et al., “Poly (acetyl, arginyl) glucosamine disrupts Pseudomonas aeruginosa biofilms and enhances bacterial clearance in a rat lung infection model”, Microbiology 2022; 168:001121, 12 pages. [cited by applicant]
Fisher et al., “Persistent bacterial infections and persister cells,” Nat. Rev. Microbiol., 2017, 15, pp. 453-464. [cited by applicant]
U.S. Appl. No. 16/572,053 US 2020/0009182, filed Sep. 16, 2019, Methods and Compositions for Disrupting Biofilm Utilizing Chitosan-Derivative Compouds, Published. [cited by applicant]
U.S. Appl. No. 16/573,559 US 2020/0009183, filed Sep. 17, 2019, Compositions and Methods of Use Thereof, Published. [cited by applicant]
Cook, Gregory M. et al: “Physiology of Mycobacteria”, In: “Physiology of Mycobacteria”, Jul. 31, 2013, vol. 55, pp. 81-319. [cited by applicant]
Jarzembowski Jason A. et al: “Nontuberculous Mycobacterial Infections”, Archives of Pathology & Laboratory Medicine, vol. 132, No. 8, Aug. 1, 2008, pp. 1333-1341. [cited by applicant]
Koh Won-Jung, “Nontuberculous Mycobacteria—Overview”, Microbiology spectrum, Jan. 1, 2017, pp. 1-7. [cited by applicant]
Extended European Search Report and Search Opinion for European Application No. 20933254.3, issued on Dec. 21, 2023, 13 pages. [cited by applicant]